Cullinan Oncology, Inc. to Participate in the H.C. Wainwright Global Life Sciences Conference
Cullinan Oncology (Nasdaq: CGEM) has announced that its CEO, Owen Hughes, will present at the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Cullinan Oncology (Nasdaq: CGEM) has announced that its CEO, Owen Hughes, will present at the H.C. Wainwright Global Life Sciences Conference on March 9, 2021, at 7:00 AM EST. The presentation will be available on-demand for registered attendees starting at that time. Cullinan specializes in developing a diverse pipeline of targeted oncology and immuno-oncology therapies, focusing on candidates with novel technology and advanced development stages.
Details
News Market Reaction – CGEM
The recorded move for CGEM in the trading session of this news was +8.06%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., March 02, 2021 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies, today announced that the company’s Chief Executive Officer, Owen Hughes, will present at the upcoming H.C. Wainwright Global Life Sciences Conference.
Event: H.C. Wainwright Global Life Sciences Conference
Date: Tuesday, March 9th
Time: 7:00am EST
Location: Virtual
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7am EST on Tuesday, March 9th, 2021, for registered attendees only.
About Cullinan Oncology
Cullinan Oncology is a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies. The Company’s strategy is to build a pipeline of therapeutic candidates that are uncorrelated across multiple dimensions, with a focus on assets that it believes have novel technology, employ differentiated mechanisms, are in a more advanced stage of development than competing candidates, or have a combination of these attributes.
Contacts:
Investor Relations
investors@cullinanoncology.com
Jeff Trigilio
+1 716.725.5019
jtrigilio@cullinanoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.